| Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis C Caussy, MH Alquiraish, P Nguyen, C Hernandez, S Cepin, LE Fortney, ... Hepatology 67 (4), 1348-1359, 2018 | 300 | 2018 |
| Link between gut‐microbiome derived metabolite and shared gene‐effects with hepatic steatosis and fibrosis in NAFLD C Caussy, C Hsu, MT Lo, A Liu, R Bettencourt, VH Ajmera, S Bassirian, ... Hepatology 68 (3), 918-932, 2018 | 170 | 2018 |
| Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease V Ajmera, ER Perito, NM Bass, NA Terrault, KP Yates, R Gill, R Loomba, ... Hepatology 65 (1), 65-77, 2017 | 169 | 2017 |
| Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function SR Sharpton, V Ajmera, R Loomba Clinical Gastroenterology and Hepatology 17 (2), 296-306, 2019 | 153 | 2019 |
| Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease V Ajmera, CC Park, C Caussy, S Singh, C Hernandez, R Bettencourt, ... Gastroenterology 155 (2), 307-310. e2, 2018 | 145 | 2018 |
| Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review VH Ajmera, NA Terrault, SA Harrison Hepatology 65 (6), 2090-2099, 2017 | 133 | 2017 |
| Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis V Ajmera, P Belt, LA Wilson, RM Gill, R Loomba, DE Kleiner, ... Clinical Gastroenterology and Hepatology 16 (9), 1511-1520. e5, 2018 | 130 | 2018 |
| TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial R Loomba, R Mohseni, KJ Lucas, JA Gutierrez, RG Perry, JF Trotter, ... Gastroenterology 161 (5), 1475-1486, 2021 | 121 | 2021 |
| Imaging biomarkers of NAFLD, NASH, and fibrosis V Ajmera, R Loomba Molecular metabolism 50, 101167, 2021 | 114 | 2021 |
| Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD N Tamaki, V Ajmera, R Loomba Nature Reviews Endocrinology 18 (1), 55-66, 2022 | 108 | 2022 |
| Gestational diabetes mellitus is strongly associated with non-alcoholic fatty liver disease VH Ajmera, EP Gunderson, LB VanWagner, CE Lewis, JJ Carr, ... Official journal of the American College of Gastroenterology| ACG 111 (5 …, 2016 | 105 | 2016 |
| Gestational diabetes mellitus is strongly associated with non-alcoholic fatty liver disease VH Ajmera, EP Gunderson, LB VanWagner, CE Lewis, JJ Carr, ... Official journal of the American College of Gastroenterology| ACG 111 (5 …, 2016 | 104 | 2016 |
| Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene–environment interaction study CA Emdin, M Haas, V Ajmera, TG Simon, J Homburger, C Neben, L Jiang, ... Gastroenterology 160 (5), 1620-1633. e13, 2021 | 88 | 2021 |
| What factors determine the severity of hepatitis A‐related acute liver failure? V Ajmera, G Xia, G Vaughan, JC Forbi, LM Ganova‐Raeva, Y Khudyakov, ... Journal of viral hepatitis 18 (7), e167-e174, 2011 | 85 | 2011 |
| A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes V Ajmera, S Cepin, K Tesfai, H Hofflich, K Cadman, S Lopez, E Madamba, ... Journal of Hepatology 78 (3), 471-478, 2023 | 79 | 2023 |
| Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease LB VanWagner, H Ning, NB Allen, V Ajmera, CE Lewis, JJ Carr, ... Gastroenterology 153 (5), 1260-1272. e3, 2017 | 78 | 2017 |
| Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease VH Ajmera, A Liu, S Singh, G Yachoa, M Ramey, M Bhargava, A Zamani, ... Hepatology 71 (3), 849-860, 2020 | 66 | 2020 |
| Machine learning enables new insights into genetic contributions to liver fat accumulation ME Haas, JP Pirruccello, SN Friedman, M Wang, CA Emdin, VH Ajmera, ... Cell genomics 1 (3), 2021 | 65 | 2021 |
| Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease N Tamaki, N Munaganuru, J Jung, AQ Yonan, RR Loomba, R Bettencourt, ... Gut 71 (5), 983-990, 2022 | 62 | 2022 |
| Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease C Caussy, VH Ajmera, P Puri, CLS Hsu, S Bassirian, M Mgdsyan, S Singh, ... Gut 68 (10), 1884-1892, 2019 | 62 | 2019 |
